Climate change cuts crop yields, even with adaptation efforts: Study
In contrast with previous research suggesting warming actually could bolster food production, a new study, published in Nature on Wednesday, finds the opposite.
For every additional degree Celsius the planet warms, its ability to produce food could decrease by 120 calories per person per day, or 4.4 percent of the current daily consumption, according to the study.
'If the climate warms by 3 degrees, that's basically like everyone on the planet giving up breakfast,' said senior author Solomon Hsiang, a professor of environmental social sciences at Stanford University, in a statement.
Another serious side effect, Hsiang warned, could be price surges that infringe upon access to food for families across the world.
U.S. agriculture is expected to suffer significant losses, particularly in the Midwest, the researchers noted.
Lead author Andrew Hultgren, an assistant professor of agricultural and consumer economics at the University of Illinois Urbana-Champaign, warned that U.S. corn and soybean production could 'just get hammered under a high warming future.'
'You do start to wonder if the Corn Belt is going to be the Corn Belt in the future,' Hultgren said in a statement.
Hsiang and Hultgren, together with more than a dozen scholars, worked over the past eight years to draw observations from more than 12,000 regions across 55 countries. They analyzed adaptation costs and yield for crops responsible for two-thirds of the planet's calories: wheat, rice, soybeans, barley and cassava.
They found that previous studies failed to consider what adaptation measures might be realistic for farmers — assuming they would implement either 'perfect' adaptation protocols or none at all.
The researchers estimated that adjustments farmers are making — such as switching crops, shifting planting and harvesting dates and altering fertilizer — could offset about a third of climate-related losses in 2100 amid rising emissions.
But the rest of the losses, they stressed, would remain.
'Any level of warming, even when accounting for adaptation, results in global output losses from agriculture,' Hultgren said.
Overall, the researchers found that yield losses could amount to about 41 percent in the wealthiest regions and 28 percent in the lowest income areas by 2100.
There is a 50 percent chance that the world's rice yields could rise, because rice thrives on warm nights, while there is a 70 percent to 90 percent chance that the other staple crops will decline, according to the study.
In the shorter-term, the authors estimated that climate change would bring down global crop production by about 8 percent by 2050, regardless of the rise or fall of emissions. This is because carbon dioxide emissions, they explained, stay in the atmosphere, trapping heat for the long haul.
Going forward, the scientists said they are working with the United Nations Development Program to raise awareness about their findings among governments. They are also creating a system to determine which communities are most at risk of declines and could benefit from targeted support.
'Farmers know how to maintain the soil, invest in infrastructure, repair the barn,' Hsiang said. 'But if you're letting the climate depreciate, the rest of it is a waste. The land you leave to your kids will be good for something, but not for farming.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson's Disease
CAMBRIDGE, Mass., August 06, 2025--(BUSINESS WIRE)--Lysoway Therapeutics, Inc., a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). Support comes from MJFF's Parkinson's Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson's disease. Lysoway Therapeutics funding of $2.93 million will support the preclinical and translational development of Lysoway's novel, highly brain-penetrant small molecule TRPML1 agonist. The study aims to investigate whether activating TRPML1 by a novel, small molecule modulator, will enhance the lysosomal membrane calcium ion channel to restore lysosomal function and help with clearance of alpha-synuclein, the protein that is linked to the disease. "We are honored to receive this generous grant from The Michael J. Fox Foundation," said Valerie Cullen, PhD, Principal Investigator and SVP of Research and Translation at Lysoway. "TRPML1 is a high value target due to its pivotal role in sensing and responding to cellular stress. By activating this ion channel, we can engage multiple beneficial pathways that restore autophagy/lysosomal homeostasis and bolster cellular resilience. Our lead development candidate is both orally bioavailable and highly brain-penetrant, offering strong potential to modify disease progression in Parkinson's Disease." Yongchang Qiu, PhD, Founder and Chief Executive Officer of Lysoway Therapeutics, added "This funding underscores growing confidence in TRPML1 as a compelling target for Parkinson's disease. It will allow us to accelerate development of our lead TRPML1 agonist and to establish key biomarkers for target engagement, with the goal of initiating first-in-human clinical trials early next year." About Lysoway Therapeutics, in Cambridge, MA, Lysoway Therapeutics is a leader in developing therapeutically viable lysosomal ion channel modulators. The company is advancing a pipeline of small molecule activators targeting these channels to treat neurodegenerative diseases. Learn more at View source version on Contacts Media contact: Info@


CNN
26 minutes ago
- CNN
HHS slashes funding for mRNA vaccine development
US Health and Human Services is 'winding down' its mRNA vaccine development and will instead fund other vaccine platforms through the Biomedical Advanced Research and Development Authority, the agency said Tuesday. HHS Secretary Robert F. Kennedy Jr. said in a statement that BARDA would terminate 22 mRNA vaccine development investments, suggesting the vaccines 'fail to protect effectively against upper respiratory infections like Covid and flu,' despite evidence they protect against severe disease and death from Covid-19 and show promise against influenza. HHS said some final stage contracts will continue, but 'no new mRNA-based projects will be initiated.' 'We reviewed the science, listened to the experts, and acted,' Kennedy said. 'Going forward, BARDA will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices,' HHS said. 'Technologies that were funded during the emergency phase but failed to meet current scientific standards will be phased out in favor of evidence-based, ethically grounded solutions – like whole-virus vaccines and novel platforms.' Messenger RNA is a single strand of the genetic code that cells can 'read' and use to make a protein. With the Covid vaccine, mRNA instructs cells in the body to make the particular piece of the virus's spike protein. When the immune system sees it, it recognizes it as foreign and is then prepared to attack when there is an actual infection. The vaccines were particularly useful during the Covid-19 pandemic because they can be developed and manufactured quickly. Multiple peer-reviewed studies have shown that mRNA vaccines developed under Operation Warp Speed during the first Trump administration were highly effective at preventing severe disease and were repeatedly demonstrated to be extremely safe. The Trump administration and Kennedy, who has a long history of anti-vaccine claims, had previously said they were evaluating mRNA projects. In May, HHS also terminated a $590 million contract with Modern to develop a vaccine to protect against bird flu. Dr. Peter Hotez, a pediatrician who directs the Center for Vaccine Development at Texas Children's Hospital, said Tuesday's HHS announcement will 'promote their pseudoscience agenda and weaken our nation's biosecurity.' 'The mRNA technology, like all biotechnologies, has strengths and weaknesses, but for a pandemic situation with a new and previously unknown pathogen, or for cancer vaccines and immunotherapeutics it has distinct advantages,' Hotez said. 'HHS under Mr. Kennedy is telling us that we should no longer look to the federal government for innovation in biomedicine. The states are on their own.' HHS said it is canceling BARDA's award to Moderna/UTMB for an mRNA vaccine for H5N1, known as avian flu. It is also terminating contracts with Emory University and Tiba Biotech. Emory has been working on a dry powder mRNA antiviral platform that could be inhaled and Tiba is working on a platform that uses a nanoparticle carrier technology, according to the BARDA website. HHS also said it is 'de-scoping' mRNA-related work in contracts it has with Luminary Labs, ModeX, and Sequirus. HHS said it was also rejecting or canceling multiple pre-award solicitations with proposals from Pfizer, Sanofi Pasteur, CSL Sequirus, Gritstone and others. And it was also restructuring collaborations with the US Department of Defense that would impact nucleic acid-based vaccine projects with AAHI, AstraZeneca and HDT Bio. HHS said the impacted projects were worth about $500 million. 'Other uses of mRNA technology within the department are not impacted by this announcement,' it said. In a statement, Moderna spokesman Kelly Cunningham said, 'We are not aware of any new contract cancellations by BARDA involving Moderna. As previously announced in May, our pandemic flu contract was canceled, and we do not currently have any active collaboration with BARDA.' A spokesperson for Gritstone said the company ceased operations 'as a company some time ago.' AstraZeneca declined to comment. CNN reached out to Tiba Biotech, Emory, Pfizer, ModeX, Luminary Labs, CSL Seqirus and Sanofi for a response. Dr. Paul Offit, a vaccine scientist at Children's Hospital of Philadelphia and an outside vaccine adviser to the FDA criticized Kennedy for making 'a policy decision again that contradicts the scientific data.' 'He has said things like the mRNA vaccines are unnecessarily dangerous,' Offit said. 'It's just wrong. I mean it's actually remarkably safe and it's effective.' 'A decision based on cutting back all this funding based on false statements is just hard to watch,' Offit added. If another pandemic comes 'we'll just be behind the eight ball again,' without additional research into mRNA vaccines. 'All it does is put us at unnecessary risk for no good reason and just a few bad reasons too,' Offit said. Dr. Jake Scott, an infectious diseases doctor in California who worked many long days treating patients during the Covid-19 pandemic, said he lost several patients early in the pandemic, but the mRNA vaccines brought major changes by safely protecting billions of people from severe disease and death. 'I cannot really convey accurately what a profound difference there was in the hospital pre vaccine and post vaccine and that was thanks to the mRNA technology,' said Scott, a clinical associate professor, medicine - infectious disease with Stanford Medicine. To hear that HHS was going to eliminate investment in mRNA vaccines, Scott said, is 'really depressing.' 'This just hits differently. It makes me sad. It's kind of heartbreaking,' said Scott.
Yahoo
28 minutes ago
- Yahoo
Most popular meteor shower, full moon to peak soon over PA. Here's when to look
A full 'sturgeon' moon will peak soon over Pennsylvania, and residents can also enjoy viewing the peak of a popular meteor shower soon after. This month's moon is referred to as the 'sturgeon moon' because of the abundance of fish typically found in late summer, according to the Farmers' Almanac. Many moon names come from Indigenous cultures. The Farmers' Almanac uses Indigenous moon names, along with monikers from colonial America and other North American sources. In addition to the sturgeon moon, August will bring the peak of the Perseid meteor shower, which the American Meteor Society describes as 'the most popular meteor shower' of the year. The Perseids will peak overnight Tuesday, Aug. 12 into Wednesday, Aug. 13, the American Meteor Society reports. The Perseid meteor shower has been active since July 14 and will end Monday, Sept. 1. The waning gibbous moon is expected to reduce the shower's visibility this year, so you might only be able to see the Perseid's brightest meteors. Here's when to see this year's sturgeon moon over Pennsylvania, plus when to catch more full moons in 2025. When will the sturgeon moon peak? The sturgeon moon will peak at 3:55 a.m. Eastern Daylight Time Saturday, Aug. 9, according to the Farmers' Almanac. AccuWeather's forecast says the night of Aug. 9 will be mostly clear in State College, with a low temperature of 63 degrees Fahrenheit. The moon generally appears full the day before and after its peak illumination. For those planning to stargaze the night of Friday, Aug. 8, you can expect clear conditions, AccuWeather reports, and the night of Sunday, Aug. 10 will be overcast and humid. The moon will rise in State College at 8:46 p.m. Aug. 9, according to online clock Time and Date. When to see more full moons in 2025 After the sturgeon moon, stargazers will have four more opportunities to see a full moon this year. Here's when to look, from Sunday, Sept. 7: Corn moon Monday, Oct. 6: Hunter's moon (supermoon) Wednesday, Nov. 5: Beaver moon (supermoon) Thursday, Dec. 4: Cold moon (supermoon The Central Pennsylvania Observers will host a free, public stargazing event from 8 to 10 p.m. Saturday, Oct. 4 at Penn State Arboretum.